REV-ERB raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
With the exception of yellow fever vaccine and Ebola vaccines, vaccines for VHFs are generally not available. For someone exposed to CCHF, ribavirin is available as post-exposure prophylaxis (PEP). Ribavirin may also help in exposure to Lassa fever. Any person who is taking care of a patient with any VHF should take multiple precautions against exposure and infection. The precautions include hand hygiene, double gloves, gowns, shoe and leg coverings, and face shields or goggles. Treatment of any VHF should involve careful donning (putting on) and doffing (taking off) procedures for PPE. A Trained Observer, or TO, is used to monitor the donning/doffing process. Lassa, CCHF, Ebola, and Marburg viruses may be particularly prone to nosocomial (hospital-based) spread. Airborne precautions should be utilized including, at a minimum, a fit-tested, HEPA filter-equipped respirator (such as an N95 mask), a battery-powered, air-purifying respirator, or a positive pressure supplied air respirator to be worn by personnel coming within 1.8 metres (six feet) of a VHF patient. Groups of patients should be cohorted (sequestered) to a separate building or a ward with an isolated air-handling system. Environmental decontamination is typically accomplished with hypochlorite (e.g. bleach) or phenolic disinfectants. Some VHF patients, notably those infected with Marburg and Ebola, are at their most infectious after death. Strict precautions should be taken including the safe transport and disinfection of the body.
The National Socialists supplanted the Social Democrats as the largest party in the Reichstag. As Communists and National Socialists together had won the majority of seats, no government coalition could be formed without one of them. Papen tried to justify his authoritarian style of government by pointing out that parliament could no longer function properly. Countering this reasoning, the Centre and the BVP tried to re-establish a working parliament by cooperation with the National Socialists, since the three parties together had attained 53% of the seats. When Papen called upon the people to "reject the dictatorship of a single party", the Centre Party agreed "without reservation", but it also stated that "with the same resolution we reject the dictatorship of the nameless party, now in power … even if cloaked with the illusion of non-partisanship". After Papen failed to get Hitler's support for his administration, the Centre began their own negotiations with the National Socialists. They started in the state of Prussia, where the Weimar Coalition had just lost its majority. An alternative majority could not be found and the Papen administration had seized this opportunity to assume control of Germany's largest state in the "Prussian coup" via presidential decree. Now, the National Socialists proposed to end this direct rule by forming a coalition with the Centre Party, promising an equal share in government.
Gobies are dorsal finned like the lumpsuckers, yet they are not related. The Rhenanids became extinct over 200 million years before the first stingrays evolved, yet they share quite a similar appearance. Sandlance fish and chameleons have independent eye movements and focusing by use of the cornea. Acanthurids and mbuna are both aggressive, brightly colored fish that feed principally on aufwuchs, although the former is found only in marine environments, while the latter is only found in freshwater Lake Malawi. Cichlids of South America and the "sunfish" of North America are strikingly similar in morphology, ecology and behavior. The peacock bass and largemouth bass are excellent examples. The two fishes are not related, yet are very similar. Peacock bass are native of South America and is a Cichla. While largemouth bass are native to Southern USA states and is a sunfish. others will surely be described (but see the results based on DNA data). The antifreeze protein of fish in the Arctic and Antarctic, came about independently. AFGPs evolved separately in notothenioids and northern cod. In notothenioids, the AFGP gene arose from an ancestral trypsinogen-like serine protease gene. Electric fish: electric organs and electrosensory systems evolved independently in South American Gymnotiformes and African Mormyridae. Eel form are independent in the North American brook lamprey, neotropical eels, and the African spiny eel.
Sources: en.wikipedia.org
The presence of a tapetum lucidum enables animals to see in dimmer light than would otherwise be possible. The tapetum lucidum, which is iridescent, reflects light roughly on the interference principles of thin-film optics, as seen in other iridescent tissues. However, the tapetum lucidum cells are leucophores, not iridophores. The tapetum functions as a retroreflector which reflects light directly back along the light path. This serves to match the original and reflected light, thus maintaining the sharpness and contrast of the image on the retina. The tapetum lucidum reflects with constructive interference, thus increasing the quantity of light passing through the retina. In the cat, the tapetum lucidum decreases the absolute threshold for vision, but does not materially change spectral sensitivity. When a tapetum lucidum is present, its location on the eyeball varies with the placement of the eyeball in the head. Apart from its eyeshine, the tapetum lucidum itself has a color. It is often described as iridescent. In tigers, it is greenish. In ruminants, it may be golden green with a blue periphery, or whitish or pale blue with a lavender periphery. In dogs, it may be whitish with a blue periphery. The color in reindeer changes seasonally, allowing the animals to better avoid predators in low-light winter at the price of blurrier vision.
NpO2 + 3 MO2 → M3NpO5 (M = K, Cs, Rb) The oxide compounds KNpO4, CsNpO4, and RbNpO4 are formed by reacting Np(VII) ([NpO4(OH)2]3−) with a compound of the alkali metal nitrate and ozone. Additional compounds have been produced by reacting NpO3 and water with solid alkali and alkaline peroxides at temperatures of 400–600 °C for 15–30 hours. Some of these include Ba3(NpO5)2, Ba2NaNpO6, and Ba2LiNpO6. Also, a considerable number of hexavalent neptunium oxides are formed by reacting solid-state NpO2 with various alkali or alkaline earth oxides in an environment of flowing oxygen. Many of the resulting compounds also have an equivalent compound that substitutes uranium for neptunium. Some compounds that have been characterized include Na2Np2O7, Na4NpO5, Na6NpO6, and Na2NpO4. These can be obtained by heating different combinations of NpO2 and Na2O to various temperature thresholds and further heating will also cause these compounds to exhibit different neptunium allotropes. The lithium neptunate oxides Li6NpO6 and Li4NpO5 can be obtained with similar reactions of NpO2 and Li2O. A large number of additional alkali and alkaline neptunium oxide compounds such as Cs4Np5O17 and Cs2Np3O10 have been characterized with various production methods. Neptunium has also been observed to form ternary oxides with many additional elements in groups 3 through 7, although these compounds are much less well studied.
== Further reading == Savulescu, Julian; Bostrom, Nick (2009). Human enhancement. Oxford: Oxford University Press. ISBN 978-0-19-929972-0. Savulescu, Julian; ter Meulen, Ruud; Kahane, Guy (2011). Enhancing human capacities. Chichester: Wiley-Blackwell. ISBN 978-1-4051-9581-2. Michael Bess (2015). Our Grandchildren Redesigned: Life in the Bioengineered Society of the Near Future. Beacon Press. ISBN 978-0-8070-5217-4. Bateman, Simone; Gayon, Jean; Allouche, Sylvie; Goffette, Jérôme; Marzano, Michela (2015). Inquiring into Human Enhancement: Interdisciplinary and International Perspectives (1 ed.). London: Palgrave Macmillan. ISBN 978-1-137-53006-6. Edwards, Gary (2016). "Enhancement". Encyclopedia of Global Bioethics. Springer International Publishing. pp. 1121–1130. doi:10.1007/978-3-319-09483-0_172. ISBN 978-3-319-09483-0. Jotterand, Fabrice; Ienca, Marcello (2024). The Routledge Handbook of the Ethics of Human Enhancement. New York: Routledge. ISBN 978-0-367-61579-6.
As of 2023, steatotic liver disease (SLD) has been chosen as an umbrella term encompassing different disease subcategories that begin with fatty accumulation (hepatic steatosis) in more than 5% of hepatocytes. When at least one metabolic risk factor is present, the condition is termed metabolic dysfunction–associated steatotic liver disease (MASLD). If there is also increased alcohol intake, the term MetALD (metabolic dysfunction and alcohol-related liver disease) is used. This is differentiated from alcohol-related liver disease (ALD), in which alcohol is the predominant cause of the steatotic liver disease. MASLD is thus distinguished from other causes (etiologies) such as cryptogenic SLD, drug-induced liver injury (DILI), and monogenic diseases. By various mechanisms and possible insults to the liver, SLD may progress to steatohepatitis (MASH), a state in which steatosis is combined with inflammation and sometimes fibrosis. MASH can then lead to complications such as cirrhosis and hepatocellular carcinoma.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.